Icosavax, Inc.

NASDAQ:ICVX

15.31 (USD) • At close February 16, 2024
Bedrijfsnaam Icosavax, Inc.
Symbool ICVX
Munteenheid USD
Prijs 15.31
Beurswaarde 769,036,610
Dividendpercentage 0%
52-weken bereik 4.75 - 16.105
Industrie Biotechnology
Sector Healthcare
CEO Mr. Adam K. Simpson
Website https://icosavax.com

An error occurred while fetching data.

Over Icosavax, Inc.

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory

Vergelijkbare Aandelen

Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc.

KZR

6.64 USD

Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

61.89 USD

Aerovate Therapeutics, Inc. logo

Aerovate Therapeutics, Inc.

AVTE

2.67 USD

Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc.

MRSN

1.5 USD

Theseus Pharmaceuticals, Inc. logo

Theseus Pharmaceuticals, Inc.

THRX

4.065 USD

Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc.

CMPX

1.46 USD

InterCure Ltd. logo

InterCure Ltd.

INCR

1.06 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)